Anti-cytomegalovirus activity of artemisinin-derived dimers
US8883765B2 · kind B2 · utility
4Cited by
0References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2010 |
| Grant date | Nov 11, 2014 |
| Priority date | — |
| Expiry date | Jan 4, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/6561
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotoxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.